Leronlimab
Monoclonal antibody used in the treatment of HIV and cancer
Leronlimab (also known as PRO 140) is a humanized monoclonal antibody that targets the CCR5 receptor. It is primarily being investigated for its potential use in the treatment of HIV/AIDS and certain types of cancer.
Mechanism of Action[edit]
Leronlimab works by binding to the CCR5 receptor, which is a protein on the surface of certain immune cells. The CCR5 receptor is used by the HIV virus to enter and infect host cells. By blocking this receptor, Leronlimab prevents the virus from entering these cells, thereby inhibiting its replication and spread.
In addition to its role in HIV treatment, the CCR5 receptor is also involved in the migration of cancer cells and the immune response to tumors. This has led to research into the use of Leronlimab as a potential treatment for metastatic cancer.
Clinical Trials[edit]
Leronlimab has undergone several clinical trials to evaluate its safety and efficacy. In HIV treatment, it has been tested as a monotherapy and in combination with other antiretroviral drugs. Results have shown that Leronlimab can significantly reduce viral load in patients with multi-drug resistant HIV.
In cancer research, Leronlimab is being studied for its ability to inhibit metastasis and improve the immune system's response to tumors. Early-phase trials have shown promising results, particularly in patients with triple-negative breast cancer.
Side Effects[edit]
The most common side effects of Leronlimab include injection site reactions, such as redness and swelling. Other potential side effects may include headache, fatigue, and nausea. As with any investigational drug, the full spectrum of side effects is still being studied.
Regulatory Status[edit]
As of 2023, Leronlimab is not yet approved by the FDA or other major regulatory bodies. It is currently available through clinical trials and expanded access programs for patients who meet specific criteria.
Also see[edit]
| Monoclonal antibodies | ||||||||
|---|---|---|---|---|---|---|---|---|
This Monoclonal antibodies related article is a stub.
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
